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ABSTRACT 
 
Many dominantly inherited disorders are caused by missense amino acid substitutions resulting from a single 
nucleotide exchange in the encoding gene. For these disorders, where proteins expressed from the mutant 
alleles are often pathogenic and present throughout life, gene silencing, through intervention at the mRNA 
level, holds promise as a therapeutic approach. We have used mutations that underlie the slow channel con-
genital myasthenic syndrome (SCCMS) as a model system to study allele-specific gene silencing of RNA 
transcripts by DNAzymes. We tested the ability of DNAzymes to give allele-specific cleavage for i) muta-
tions that create cleavage sites, and ii) mutations located close to a DNAzyme cleavage site that create a po-
tential mismatch in the binding arms.  For both we demonstrate selective cleavage of mutant transcripts un-
der simulated physiological conditions. For DNAzymes with binding arm mismatches the degree of selectiv-
ity for mutant over wild type may be enhanced by optimising the mismatch position as well as the binding 
arm length. The optimal sites for mismatches are 1.1 and 1.2 in arm I, and 16.2 in arm II. Asymmetric bind-
ing arm DNAzymes with a shorter arm I are more discriminative. Our results show it should be possible to 
apply DNAzyme-mediated cleavage of mutant alleles even when the mutant does not itself create a putative 
cleavage  site.  This  therapeutic  approach  may  be  well  suited  to  dominantly  inherited  disorders  such  as 
SCCMS, where loss of some wild type transcripts is unlikely to have pathogenic consequences.  
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INTRODUCTION 
 
To devise successful therapy for dominant genetic disor-
ders is a challenging goal.  These disorders are often both 
progressive and incurable. An optimal therapy requires the 
elimination of the pathogenic mutant protein without det-
rimental effects on the protein generated from the corre-
sponding  wild  type  allele.  One  approach is  to  preferen-
tially target the mutant transcripts using the antisense cata-
lytic  nucleic  acids,  hammerhead  ribozymes  (Fedor  and 
Uhlenbeck,  1990)  or  their  DNA  analogues,  DNAzymes 
(Santoro and Joyce, 1997). 
 
DNAzymes are short oligonucleotides that have the capac-
ity  to  cleave  RNA  molecules  in  an  enzymatic  fashion. 
They consist of a central catalytic motif flanked by two 
arms (arm I and II) of complementary sequence that bind 
to the target RNA molecules on a Watson-Crick basis (see 
Figure 1A). The catalytic activity is metal ion-dependent 
and breaks the phosphodiester bond between purine and 
pyrimidine  nucleotides  (Santoro  and  Joyce,  1998).  Like 
hammerhead  ribozymes  (reviewed  in  Wood  et al,  2003; 
Bagheri and Kashani-Sabet, 2004) DNAzymes have been 
used to suppress pathogenic genes in a growing number of 
disease models  (reviewed in (Khachigian,  2002; Achen-
bach et al, 2004). Most recently, LMP1 mRNA in Epstein-
Barr virus-mediated carcinogenesis was successfully tar-
geted in vivo (Lu et al, 2005).  However, the potential of 
DNAzymes as  a therapy  for  dominant  genetic  disorders 
has not yet been explored.  
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To test the ability of DNAzymes to cleave mutant cRNA 
sequences we used mutations underlying the slow channel 
congenital myasthenic syndrome (SCCMS). Thus far, 18 
different  SCCMS  mutations  have  been  described  (Ohno 
and Engel, 2004). It is thought that prolonged activation of 
the receptors, due to the mutations, leads to excess calcium 
entry  resulting  in  an  “endplate  myopathy”  and  muscle 
weakness  (Engel et al, 1982; Gomez et al, 2002). Thus 
SCCMS is an example of a dominant excitotoxic disorder 
caused by “gain of function” mutations.  At the neuromus-
cular junction, the safety margin for neuromuscular trans-
mission is only compromised if AChR levels fall below 
around  30%  of  normal (Engel et al, 2003) and thus for 
gene silencing strategies problems arising from happloin-
sufficiency should not be a problem. 
 
Allele-specific  cleavage  of  mutant  RNA  transcripts  by 
catalytic nucleic acids normally depends on the mutation 
itself  creating  a  cleavage  site  (Figure  1B(i)).  However, 
single nucleotide mutations will not always result in the 
creation of a cleavage site that can be used to discriminate 
between wild type and mutant transcripts, apparently limit-
ing this strategy. Here, we also adopt an alternative ap-
proach for targeting mutant alleles by identifying putative 
cleavage sites near the mutation, and then designing the 
DNAzyme  binding  arm  to  target  the  mutant  sequence, 
creating a mismatch with the wild type (Figure 1B(ii)). 
 
MATERIALS AND METHODS 
 
DNAzyme design and synthesis 
DNAzymes  bearing  the  10-23  catalytic  motif  were  de-
signed with different binding arm lengths and were syn-
thesised as standard oligonucleotides (Invitrogen). To fa-
cilitate  DNAzyme  nomenclature,  we  refer  to  them,  for 
example, as αS269IAII5(13+9), where αS269I is the target 
substrate, AII is arm II, 5 is the distance of the mismatch 
from the cleavage site, and (13+9) indicates the lengths of 
arm II and arm I respectively (see Figure 3A). DNAzymes 
that  directly  cleave  the  target  are  termed,  for  example, 
εL221F(6+12), where  εL221F is the target substrate and 
(6+12) are the lengths of the binding arms (Figure 2). 
 
cRNA substrate preparation 
Missense mutations that underlie SCCMS were introduced 
by  the  Sculptor™    in  vitro  mutagenesis  system  (Amer-
sham  Biosciences).    Plasmids  harbouring  the  mutant 
cDNA were checked  by  DNA sequencing. 
32P-  labelled 
cRNA  substrates containing the full coding sequence  of 
mutant and wild-type subunits were synthesised using the 
Megascript™ T7 in vitro transcription kit (Ambion Bio-
sciences). 
 
In vitro cleavage  
Substrate cRNA and DNAzymes were incubated either in 
10 mM MgCl2, 50 mM Tris.HCl, pH 7.5 or under simu-
lated physiological conditions (Santoro and Joyce, 1997) 
(2 mM MgCl2, 150 mM KCl, 50 mM Tris.HCl, pH 7.5, 
37
oC) for 4 hr. The reactions were carried out under single 
turn  over  conditions  (i.e.  with  excess  enzymes)  using  a 
molar  ratio  for  enzyme:substrate  of  10:1.  The  reactions 
were loaded on to a 6% (w/v) denaturing polyacrylamide 
gel and run at 200V for 7 hr. Gels were dried and exposed 
overnight to a phosphor storage screen (Fuji) and scanned 
in a PhosphorImager (Fuji). The amount of cleavage prod-
ucts were expressed as a percentage of the total of cleaved 
and uncleaved material (see below).   
 
Calculations of % of cleavage and selectivity 
The  percentage  of  cleavage  was  calculated  as 
(P1+P2/P1+P2+S) x 100 where P1 and P2 are the 5’ and 
3’products, and S is the substrate as previously described 
by Werner and Uhlenbeck (1995). The catalytic activities 
of mismatched DNAzymes were calculated by normalising 
the percentage of cleavage to the matched ones as % activ-
ity  =  %  cleavage  mismatched  DNAzyme  /  %  cleavage 
matched DNAzyme x 100. The degree of selectivity was 
calculated as (100 –  mismatched activity). 
 
RESULTS 
 
Cleavage of cRNA transcripts at the site of mutation 
DNAzymes with the 10-23 catalytic core can cleave RNA 
specifically at RY junctions, where R = A or G, and Y = U 
or C (Santoro and Joyce, 1997). εL221F and αS269I are 
two missense mutations that reside in different AChR sub-
unit genes (Croxen et al, 1997; Croxen et al, 2002). Each 
underlies a SCCMS and also creates putative DNAzyme 
cleavage sites. εL221F results from a C to T transition at 
nucleotide position 661, creating a GU cleavage site in the 
mRNA, and αS269I, which results from a G to T nucleo-
tide substitution at position 806, creates an AU cleavage 
site.  The  DNAzyme  εL221F(6+12)  (see  methods  for 
DNAzyme  nomenclature)  was  designed  to  target  the 
εL221F mutation. In vitro cleavage showed εL221F(6+12) 
cleaved its cRNA target (Figure 2), whereas the wild-type, 
which lacks the cleavage site, was not cleaved, thus dem-
onstrating the discriminatory nature of the DNAzyme. To 
confirm the catalytic activity, an inactive DNAzyme with 
the same arms but with two nucleotides (C → T at position 
3 and A → G at position 12) mutated in the catalytic core 
was used as a control. No cleavage was detected after in-
cubation with this inactive DNAzyme. Similar results were 
obtained for a second target, αS269I within the α-subunit 
gene transcript, with the DNAzyme αS269I(13 +13) (data 
not shown).  
 
Selective  cleavage  of  mutant  transcripts  through 
mismatches in the binding arms  
To target mutations that do not introduce cleavage sites we 
identified  putative  cleavage  sites  near  the  mutation  and 
designed DNAzymes  with  arms  that  perfectly  match  the 
mutant sequence but have a mismatch in the binding arm 
for the wild type counterpart (Figure 1B(ii)). Thus, both 
wild  type  and  mutant  cRNA  have  the  same  DNAzyme 
cleavage site, but differ through the binding arm mismatch 
with the wild type sequence. Selectivity is obtained through 
the effects of the mismatch on cleavage activity. In these 
experiments we measured the efficacy of the DNAzyme in 
terms of selectivity rather than cleavage efficiency.  
 
SCCMS mutation αS269I  has two additional GU cleavage 
sites  in  close  proximity  either  side  of  the  AU  mutation 
cleavage  site.  We  examined  the  binding  arm  mismatch 
approach by targeting these two GU cleavage sites. Two 
asymmetric DNAzymes were designed.  αS269IAI5(9+13)   
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Figure 1. (A)  The structure of the 10-23 DNAzyme. The top 
strand is an RNA substrate with an RY cleavage site, where R 
represents A or G and Y represents U or C. Arms I and II are 
antisense binding arms. (B) Schematic diagram showing the 
steps involved in targeted cleavage of mutant transcripts by 
DNAzymes. (i) Allele-specific cleavage of mutations that create 
a DNAzyme cleavage site. (ii) Allele-specific cleavage using 
mismatches in the binding arms. 
 
 
targets the cleavage site five nucleotides upstream of the 
mutation creating a mismatch with wild type in arm I at 
position 1.5. The second cleavage site was targeted by the 
αS269IAII5(13+9) DNAzyme creating the mismatch with 
the wild type in arm II at position 16.5 (see Figure 1A for 
nomenclature). Under simulated physiological conditions 
αS269IAI5(9+13)  DNAzyme  cleaved  43%  of  the  mis-
matched  target  (wild  type)  compared  with  72%  of  its 
matched  one  (mutant),  giving  a  degree  of  selectivity  of 
39%.  The  αS269IAII5(13+9)  DNAzyme,  which  cleaved 
57% of the mutant transcript,  showed a dramatic reduc-
tion for the wild type target, cleaving only 3%, which was 
at least 20-fold less than its matched mutant counterpart 
giving  95%  selectivity  (Figure  3A).  A  second  SCCMS 
mutation in the AChR α subunit was targeted. αV156M 
results from a G to A nucleotide substitution at nucleotide 
position  466  (Croxen  et  al,  1997),  it  does  not  create  a 
cleavage site but has two putative cleavage sites in close 
proximity. Consequently, DNAzyme  αV156MAI3(10+10), 
was designed to target the cleavage site three nucleotides 
upstream of the mutation site, creating a mismatch with 
the wild type cRNA in arm I at position 1.3. Similarly, 
DNAzyme  αV156MAII6(10+10)  created  a  mismatch  in 
arm II at 16.6. αV156MAII6(10+10) cleaved 25% of the 
mismatched wild type, and  75%  of the  matched  mutant 
substrate.  αV156MAI3(10+10)  showed  an  even  greater 
difference in activity, cleaving only 11% of the wild type 
but 61% of the mutant (Figure 3B). 
 
Optimization of the DNAzyme design to enhance the 
mismatch-based selectivity 
i. The effect of the position of the mismatch  
Targeting  the  cleavage  sites  either  side  of  αS269I  and 
αV156M revealed differing effects of the mismatch posi-
tion along arm I and arm II in reducing cleavage activity 
and  hence  the  degree  of  selectivity.  For  αS269I, 
DNAzymes with the same arm length (9+13), but different 
mismatch positions, 1.5 in arm I for αS269IAI5(9+13) and 
16.5  in  arm  II  for  αS269IAII5(9+13),  showed  dramatic 
changes in the degree of selectivity (39% and 4% respec-
tively) (Figure 4A). Similarly, targeting the two cleavage 
sites either side of the αV156M mutation with the same 
arm  length  (9+13)  but  different  positions  for  the  mis-
matches,  1.3  for  αV156MAI3(9+13)  and  16.6  for 
α156AII6(9+13), also showed different degrees of selec-
tivity (74% and 55% respectively) (Figure 4A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  In vitro cleavage of cRNA transcripts containing the 
εL221F missense mutation that is created by a C to T transition  
at nucleotide position 661 in the AChR ε subunit. DNAzymes 
were incubated with cRNA substrates for 4 hr at 37
oC, and prod-
ucts were size fractionated on a 3% (w/v) agarose gel, stained by 
ethidium bromide and visualised under UV. Lane 1, W/aDz, wild 
type cRNA incubated with active DNAzyme; lane 2, W/iDz, 
mutant cRNA incubated with inactive DNAzyme; lane 3, M, 
mutant cRNA; lane 4, M/aDz, mutant cRNA transcripts incu-
bated with an active DNAzyme. Cleaved products and their sizes 
are indicated by arrows. 
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Figure 3.  Selective cleavage of cRNA containing mutations 
αS269I and αV156M using mismatches in the DNAzyme binding 
arms.
 32P-labelled cRNA substrates were incubated with 
DNAzymes for 4 hr under simulated physiological conditions. 
Cleaved products were size fractionated on a 6% polyacrylamide 
gel and visualised by autoradiography. (A) (i) αS269I. Lane 1, 
αS269I cRNA; lane 2, αS269I cRNA incubated with DNAzyme 
αS269IAI5(9+13); lane 3, wild type cRNA incubated with 
αS269IAI5(9+13); lane 4,  αS269I cRNA incubated with 
DNAzyme αS269IAIII5(13+9); lane 5; wild type cRNA incu-
bated with αS269IAIII5(13+9); lane 6, wild type cRNA. (ii)  % 
cleavage obtained by quantification of 
32P signals using a phos-
phorImager. Data are calculated from 5 separate experiments. (B) 
(i) αV156M. Lane 1, wild type cRNA; lane 2, wild type cRNA 
incubated with DNAzyme αV156MAI3(10+10); lane 3, 
αV156M-cRNA incubated with αV156MAI3(10+10); lane 4, 
wild type cRNA incubated with DNAzyme 
αV156MAIII6(10+10); lane 5, αV156M-cRNA incubated with 
DNAzyme αV156MAIII6(10+10); lane 6, wild type cRNA. (ii) 
% cleavage obtained by quantification of 
32P signals using a 
phosphorImager. Values represent mean ± SD of 5 experiments. 
To investigate further the effect of the mismatch position 
on cleavage efficiency, a set of DNAzymes were designed 
to target the n472AU site close to the αV156M mutation.  
Symmetrical (10+10) DNAzymes were designed with se-
quential mismatches in the binding arms for the  mutant 
target, arm I (1.1, 1.2, 1.3, 1.4, 1.5) and arm II (16.1, 16.2, 
16.3,  16.4,  16.5).  The  cleavage  efficiency  of  each  mis-
matched  enzyme  was  normalised  to  the  matching  one 
(Figure 4B). For arm I, a mismatch at position 1.1 showed 
no cleavage. This is to be expected since it is a required 
position for cleavage.  A mismatch at position 1.2 gave 
very low cleavage activity (15%). As the distance of the 
mismatch from the cleavage site increases, the enzymes 
become more tolerant. Position 1.3 mismatch showed 44% 
activity, which is 2-fold less than the matched substrate.  
Positions 1.4 and 1.5 reduced the cleavage by 2.3- and 2-
fold  respectively.  By  contrast,  except  for  position  16.2, 
mismatches in arm II have less effect on catalytic activity. 
In  general  a  mismatch  in  helix  I  had  a  far  more  pro-
nounced effect than a  mismatch in arm II,  suggesting a 
vital role for this arm in establishing the DNAzyme cata-
lytic activity.  
 
ii. The effect of binding arm length 
We then examined the effect of the binding arm length on 
the  two  mutant  cRNA  substrates, αS269I  and  αV156M. 
For the αV156M mutation, over 70% selectivity was ob-
tained with three DNAzymes with different length binding 
arms,  αV156MAI3(9+13),  αV156MAI3(13+9)  and 
αV156MAI3(10+10), when the mismatch is at position 1.3 
in arm I (Figure 4Ci). However, when the mismatch lies 
further from the cleavage site, such as at position 1.5, the 
length of the binding arm appears to affect the degree of 
selectivity.  DNAzyme  αS269IAI5(13+13),  which  targets 
the GU site five nucleotides upstream of the αS269I muta-
tion, showed only 14%  selectivity. Shortening the arms to 
(10+10)  dramatically  increases  the  selectivity  to  69% 
(Figure 4Cii). Although, no general rule can be applied to 
all cases (as exemplified by the results in figure 4Ciii) our 
data suggests that of the various possibilities for the mis-
match location and binding arm length, the selectivity is 
likely  to be  greatest when the  mismatch is  close  to  the 
cleavage site and in a short binding arm (Figure 4Civ). 
 
DISCUSSION 
 
DNAzymes may provide a tool for gene silencing in vivo, in 
particular if stabilised by phosphoramidate or locked nucleic ac-
ids (Takahashi et al, 2004;  Vester et al, 2004). We show selec-
tive cleavage by DNAzymes of missense mutations that 
underlie  a  dominantly  inherited  disorder.  If  a  mutation 
creates  a  putative  cleavage  site,  DNAzymes  can  be  de-
signed to target specifically the mutant transcripts leaving 
the wild-type counterpart intact. cRNA transcripts contain-
ing the SCCMS mutations εL221F or αS269I were cleaved 
at  the  mutation  site,  while  the  wild  type  transcripts  re-
mained uncut, thus providing a method of selectively tar-
geting the mutant allele. We also investigated whether we 
could  obtain  selective  cleavage  of  mutant  transcripts 
through mismatches in binding arms I and II. Under simu-
lated  physiological  conditions  a  single  nucleotide  mis-
match in the binding arm reduced the catalytic activity of 
DNAzymes,   thus  generating  the  ability  to  discriminate  
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Figure 4. (A)  Effects of the mismatch position on DNAzyme cleavage activity. (a) The effects of the position of the binding arm 
mismatch in targeting the two cleavage sites located either side of αS269I. The mismatches are in arm I and arm II, both 5 nucleo-
tides from the mutation. The sequence of the binding arms are shown, and the position of the mismatch indicated in the diagrams. 
The cleaved products and the calculated degree of selectivity for mutant versus wild type cRNA transcripts are shown. 
(B) The effect of the position of the binding arm mismatch on the DNAzyme cleavage site at nucleotide position α472. 
32P-labelled 
cRNA for wild type or mutant αV156M AChR α subunits were synthesised in vitro and incubated with the DNAzymes under simu-
lated physiological conditions for 4 hr. Cleaved products were run on 6% (w/v) polyacrylamide gels and subjected to autoradiogra-
phy. (i) Example autoradiograph showing in lane 1, αV156M cRNA; lanes 2-6, DNAzymes with mismatches in helix III; lane 7, 
DNAzyme matched to the mutant transcript; lanes 8-12, DNAzymes with mismatches in helix I. (ii) Cleavage activity normalised to 
the activity for the matched arms. Values represent mean ± SD of 5 experiments. (C)  Effects of binding arm length on selectivity 
due to binding arm mismatches. 
32P-labelled cRNA substrates containing the wild type sequence or SCCMS mutations were incu-
bated with the indicated DNAzymes that contain mismatches in arm I or arm II and have binding arms of varying length. Diagram-
matic representations of the DNAzymes (left) and calculated degree of selectivity (right) are shown. (i)  αV156M cRNA transcripts 
incubated with DNAzymes targeting the cleavage site 3 nucleotides upstream of the mutation. (ii) αS269I cRNA cleaved by symmet-
ric DNAzymes of differing arm length with the mismatch to the wild type helix I at position 1.5. (iii) αS269I cRNA cleaved at the 
upstream or downstream DNAzyme sites (AI5 or AII5) with variation of the DNAzyme binding arm length. (iv) DNAzymes targeted 
to α-subunit cRNAs containing three different cleavage sites, illustrating that greater selectivity is obtained with mismatches in the 
shorter binding arm.
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between mutant and wild-type RNA transcripts. We found 
that mismatches in arm I reduce the catalytic activity more 
than  mismatches  in  arm  II  (except  for  arm  II  position 
16.2). The degree of selectivity may be enhanced by opti-
mising the position of the mismatch as well as the binding 
arm length. Positions 1.2 and 16.2 were the most sensitive, 
correlating  with  results  from  mismatch  studies  on  ham-
merhead ribozymes (Sun et al, 1995; Werner and Uhlen-
beck, 1995), and the greatest discrimination was obtained 
by generating asymmetric DNAzymes with a shorter arm I. 
 
The reduction in DNAzyme activity due to the mismatches in 
the arms  varied according  to the length  and the  mismatch 
position. Our results, which were obtained using long cRNA 
transcripts, correlated well with previous studies on the influ-
ence  of arm length asymmetry  and  base substitutions  per-
formed on a short target substrate (Cairns et al, 2000a; Cairns 
et al, 2000b). We found that, in general, mismatches in arm I 
are more effective in reducing the enzyme activity and thus 
increasing the degree of selectivity, although this is not al-
ways the case. For example, αS269IAII5(13+9), with a mis-
match at 16.5 in arm II, showed a very high degree of selec-
tivity  of  95%,  compared  with  45%  for  its  counterpart 
αS269IAI5(13+9) with the mismatch in arm I at position 1.5. 
Factors such as target site and sequence composition of the 
arms may influence the catalytic activity of the DNAzyme 
(Santoro and Joyce, 1998; Cairns et al, 1999). In addition, the 
nature of the mismatch will influence the catalytic properties 
of DNAzymes; for instance, the wobble mismatch (G:U) is 
likely to cause least disruption to binding. 
 
Having located the most sensitive positions for placing mis-
matches, we tested the effect of altering the arm length for both 
symmetric and asymmetric DNAzymes. The principle of mis-
match-mediated selectivity is based on weakening the enzyme-
substrate binding which leads to a reduction in the cleavage 
activity. Thus, as expected, mismatches in shorter arms give 
greater selectivity. However, we also noted the dominant role 
of arm I in governing catalytic activity, suggesting that short-
ening arm I as opposed to arm II may be used to enhance 
selectivity without compromising cleavage efficiency.  
 
CONCLUSIONS 
 
• DNAzymes  provide  a  potential alternative  to  RNAi  or 
ribozymes for allele-specific silencing. 
 
• DNAzymes  can  target  allele-specific  RNA  transcripts 
where a mutation introduces a cleavage site. 
 
• Where  a  mutation  does  not  introduce  a  cleavage  site, 
DNAzymes may be designed to preferentially target the 
mutant allele through mismatches in the binding arms.   
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